Ergomed’s full year results highlight continued progression and robust growth in its services business. We are expecting three of the group’s co-development partnerships are on track to deliver clinical data in 2016 with positive data providing value inflection points. The group continues to be in discussions for potential new co-development deals and we look forward to them being announced during 2016. We continue to favour Ergomed’s integrated business model of services provision and co-development, with provides low-risk exposure to ongoing drug development programmes. We remain at Buy.
